文献速递药物不良反应与药物警戒特殊人群用药

隐性ADR入院:一种识别药物相关住院的新型行政数据方法

Implied ADR-Admissions: A Cohort Study Introducing a Novel Administrative Data Approach for Identifying Drug-Related Hospitalisations.
PubMed 文献 · Drug Saf · 2025-09-16

本研究在苏格兰两个健康委员会纳入123,662名≥40岁多重用药者,提出并评估「隐性ADR入院」这一可扩展方法,将15种不良事件与既往90天药物暴露关联。1年内2.6%发生隐性ADR入院,高于明确编码ADR入院(0.4%),而低于广义不良事件入院(5.7%);胃肠出血的隐性ADR入院发生率是可预防ADR入院的20倍。该方法相对广义不良事件定义提高特异性,相对仅依赖明确ADR编码或既定用药错误的方法提高敏感性,但常规使用前仍需进一步验证。

要点

  • 隐性ADR入院1年发生率为2.6%,明确ADR入院仅0.4%。
  • 胃肠出血隐性ADR入院发生率是可预防ADR入院的20倍。
  • 既往低钾血症相关住院与潜在不适当用药是隐性ADR入院的预测因素。

核心结论

  • 隐性ADR入院方法相对广义不良事件定义提高了特异性,相对仅依赖明确ADR编码或既定用药错误的方法提高了敏感性。
  • 该方法可作为药物警戒的可扩展自动化工具,但常规用于用药安全监测前仍需进一步验证。

研究设计与样本

  • 回顾性队列研究,使用苏格兰两个健康委员会123,662名≥40岁多重用药者的链接健康数据。
  • 隐性ADR入院定义为:既往90天内存在与药物暴露 plausibly 相关的15种不良事件之一(基于结构化共识过程)的急诊住院。
  • 发生率与三种现有方法比较:不良事件入院(不论药物暴露)、明确ADR入院(明确编码为ADR)和可预防ADR入院(有既往用药错误)。
  • 采用多因素logistic回归识别隐性ADR入院的预测因素。

主要发现

  • 1年内2.6%发生隐性ADR入院,5.7%发生不良事件入院,0.4%发生明确ADR入院。
  • 胃肠出血的隐性ADR入院发生率是可预防ADR入院发生率的20倍。
  • 隐性ADR入院的关键预测因素包括既往低钾血症相关住院和潜在不适当用药的使用。

关键数值与推荐

  • 隐性ADR入院与15种不良事件相关,基于结构化共识过程确定,时间窗为既往90天。
  • 胃肠出血隐性ADR入院发生率是可预防ADR入院发生率的20倍。

临床怎么用

  • 可利用行政数据自动化识别与药物暴露时间相关的急诊入院,作为药物警戒信号来源。
  • 对有多重用药、既往低钾血症相关住院或使用潜在不适当用药的患者,可重点关注隐性ADR入院风险。

局限性

  • 原文指出该方法在常规用于用药安全监测前仍需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adverse drug reactions (ADRs) are a key contributor to unplanned hospitalisations, particularly in patients with polypharmacy. Traditional detection methods, such as expert reviews or diagnostic coding, are limited in scalability and sensitivity. OBJECTIVE: This study introduces and evaluates a novel scalable method, implied ADR-admissions, that links drug exposures to adverse events using administrative data to improve the detection of plausible drug-related hospitalisations. METHODS: A retrospective cohort study was conducted using linked health data from 123,662 individuals aged ≥ 40 years with polypharmacy in two Scottish health boards. Implied ADR-admissions were defined as emergency hospitalisations with one of 15 adverse events plausibly linked to drug exposure (based on a structured consensus process) within the prior 90 days. Incidence was compared with three existing approaches: adverse event-admissions (regardless of drug exposure), explicit ADR-admissions (explicitly coded as ADRs) and preventable ADR-admissions (with prior medication error). Multivariate logistic regression was used to identify predictors of implied ADR-admissions. RESULTS: Over 1 year, 2.6% experienced an implied ADR-admission, compared with 5.7% with adverse event-admissions, and 0.4% with explicit ADR-admissions. For gastrointestinal bleeding, the implied ADR-admission incidence was 20 times higher than the preventable ADR-admission incidence. Key predictors for implied ADR-admissions included prior hypokalaemia-related hospitalisation and use of potentially inappropriate medications. CONCLUSIONS: The implied ADR-admission approach has improved specificity relative to broad adverse event definitions while enhancing sensitivity beyond methods that rely solely on explicit ADR codes or pre-specified medication errors. It offers a scalable automated tool for pharmacovigilance, though further validation is needed prior to routine use in medication safety monitoring. Taking many medications (called polypharmacy) can increase the risk of harmful side effects, which sometimes lead to emergency hospital visits. However, these drug-related hospitalisations are often missed because they are difficult to detect with current methods. This study tested a new way to spot these cases using healthcare records. It looked at over 120,000 people aged 40 years or older in Scotland who were taking multiple medications. The method linked medications to hospital events and found that one in seven first emergency admissions of the year in these patients were likely caused by medicines—much more than what is usually reported. The most common problems were falls and bleeding, especially in those taking blood thinners. This new approach could help healthcare providers better track and prevent harm from medicines by focusing on risky drugs and vulnerable patients.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Schechner M, Rottenkolber M, Weglage C, et al. Implied ADR-Admissions: A Cohort Study Introducing a Novel Administrative Data Approach for Identifying Drug-Related Hospitalisations. Drug Saf. 2025. PMID: 40956484. doi:10.1007/s40264-025-01614-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。